lnc-TMEM132D-AS1 in the plasma of patients with NSCLC who developed resistance to osimertinib was approximately 3.52-fold higher than in patients who were sensitive to osimertinib. The gene discussed is TMEM132D; the disease is non-small cell lung carcinoma.